Shares of Amarin (AMRN -3.5%) give back much of yesterday's pop on news that Teva Pharmaceutical...

Shares of Amarin (AMRN -3.5%) give back much of yesterday's pop on news that Teva Pharmaceutical (TEVA) and Par Pharmaceutical (PRX) lost their bid to sell the generic form of Lovaza. The stock had rocketed higher on perceptions that the court ruling would clear the way for Amarin's AMR101 to launch and price without competition from generic Lovaza products.

From other sites
Comments (2)
  • Steve Rosenman
    , contributor
    Comments (765) | Send Message
    The pop was legit, and AMRN is a powder keg about to blow. It has everything going for it.
    30 May 2012, 02:25 PM Reply Like
  • tickerwatcher
    , contributor
    Comment (1) | Send Message
    Interesting all the hype with Amarin considering they do not any sales of product yet, just a lot of speculation. I am watching the new kid on the block, Pivotal Therapeutics, PVTTF:US who already have their Omega3 product being prescribed by doctors and are showing sales NOW! Very cheap stock since it is a new upstart, but do check out their management team & board, very impressive....could be a real sleeping giant.
    4 Jun 2012, 04:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs